BIO Valuation

Bio Rad Laboratories Inc

Add to Watchlist

Advanced Chart

319.550

+14.94(4.905%)1D

BIO Relative Valuation

BIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIO is overvalued; if below, it's undervalued.

Historical Valuation

Bio Rad Laboratories Inc (BIO) is now in the Fair zone, suggesting that its current forward PE ratio of 29.90 is considered Fairly compared with the five-year average of 36.62. The fair price of Bio Rad Laboratories Inc (BIO) is between 276.70 to 474.74 according to relative valuation methord.

Relative Value

Fair Zone

276.70-474.74

Current Price：319.55

Fair

29.90

Trailing

Forward

17.32

EV/EBITDA

Bio Rad Laboratories Inc. (BIO) has a current EV/EBITDA of 17.32. The 5-year average EV/EBITDA is 22.71. The thresholds are as follows: Strongly Undervalued below 8.22, Undervalued between 8.22 and 15.47, Fairly Valued between 29.96 and 15.47, Overvalued between 29.96 and 37.20, and Strongly Overvalued above 37.20. The current Forward EV/EBITDA of 17.32 falls within the Historic Trend Line -Fairly Valued range.

25.01

EV/EBIT

Bio Rad Laboratories Inc. (BIO) has a current EV/EBIT of 25.01. The 5-year average EV/EBIT is 29.31. The thresholds are as follows: Strongly Undervalued below 11.91, Undervalued between 11.91 and 20.61, Fairly Valued between 38.01 and 20.61, Overvalued between 38.01 and 46.71, and Strongly Overvalued above 46.71. The current Forward EV/EBIT of 25.01 falls within the Historic Trend Line -Fairly Valued range.

319.55

Bio Rad Laboratories Inc. (BIO) has a current PS of 319.55. The 5-year average PS is 6.06. The thresholds are as follows: Strongly Undervalued below -34.46, Undervalued between -34.46 and -14.20, Fairly Valued between 26.32 and -14.20, Overvalued between 26.32 and 46.58, and Strongly Overvalued above 46.58. The current Forward PS of 319.55 falls within the Strongly Overvalued range.

0.00

P/OCF

Bio Rad Laboratories Inc. (BIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 20.95. The thresholds are as follows: Strongly Undervalued below -6.32, Undervalued between -6.32 and 7.32, Fairly Valued between 34.59 and 7.32, Overvalued between 34.59 and 48.22, and Strongly Overvalued above 48.22. The current Forward P/OCF of 0.00 falls within the Undervalued range.

0.00

P/FCF

Bio Rad Laboratories Inc. (BIO) has a current P/FCF of 0.00. The 5-year average P/FCF is 27.97. The thresholds are as follows: Strongly Undervalued below -7.62, Undervalued between -7.62 and 10.18, Fairly Valued between 45.76 and 10.18, Overvalued between 45.76 and 63.56, and Strongly Overvalued above 63.56. The current Forward P/FCF of 0.00 falls within the Undervalued range.

Bio Rad Laboratories Inc (BIO) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 1.20 , the current P/B ratio is approximately 7.04% higher. Relative to its 5-year average P/B ratio of 1.38, the current P/B ratio is about -7.02% higher. Bio Rad Laboratories Inc (BIO) has a Forward Free Cash Flow (FCF) yield of approximately 3.95%. Compared to its 3-year average FCF yield of 2.49%, the current FCF yield is approximately 58.67% lower. Relative to its 5-year average FCF yield of 2.56% , the current FCF yield is about 53.82% lower.

1.28

P/B

Median3y

1.20

Median5y

1.38

3.95

FCF Yield

Median3y

2.49

Median5y

2.56

Competitors Valuation Multiple

The average P/S ratio for BIO's competitors is 149.61, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO) exhibits a P/S ratio of 319.55, which is 113.59% above the industry average. Given its robust revenue growth of 0.50%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIO.N

Bio Rad Laboratories Inc

Performance Decomposition

Market capitalization of BIO decreased by 6.16% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.30 to -13.01.

The secondary factor is the Revenue Growth, contributed 0.50%to the performance.

Overall, the performance of BIO in the past 1 year is driven by P/E Change. Which is more unsustainable.

0.50%

649.73M → 653.00M

Revenue Growth

-152.08%

100.53 → -52.36

Margin Expansion

145.42%

-5.30 → -13.01

P/E Change

-6.16%